CL King downgraded Axonics to Neutral from Buy after the company entered into a definitive agreement to be acquired by Boston Scientific (BSX) for $71 in cash per share, representing an equity value of approximately $3.7B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX:
- Axonics downgraded to Equal Weight from Overweight at Wells Fargo
- NeuroPace price target raised to $17 from $12 at Lake Street
- Axonics downgraded to Peer Perform from Outperform at Wolfe Research
- Axonics downgraded to Sector Perform from Outperform at RBC Capital
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
